#1 Clinical Trials Search in Europe

Study of Loncastuximab Tesirine and Rituximab for Untreated Unfit or Frail Patients with Diffuse Large B-cell Lymphoma

1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL), which is a common form of non-Hodgkin lymphoma. The study is exploring the effectiveness of a treatment combination involving two medications: Loncastuximab Tesirine and Rituximab. Loncastuximab Tesirine, also known by its code name ADCT-402, is a type of medication called a monoclonal antibody, which is designed to target and destroy cancer cells. Rituximab is another monoclonal antibody that is commonly used to treat certain types of lymphoma.

The purpose of this study is to evaluate how well this combination treatment works in patients who have not been treated before and are considered unfit or frail due to age or other health conditions. The study will involve two groups of patients. One group will include those who are unfit, and the other will include those who are frail or have heart-related health issues. The treatment will be given through an infusion, which means the medication is delivered directly into the bloodstream through a vein.

Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to understand how well the treatment works and how well patients tolerate it. The trial will also look at the safety of the treatment and any side effects that may occur. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

1 joining the study

Upon joining the study, you will be informed about the trial’s purpose and procedures. You will be asked to provide consent to participate in the study.

2 initial assessment

An initial assessment will be conducted to confirm your eligibility. This includes a review of your medical history and a physical examination.

Laboratory tests will be performed to ensure your organ functions are adequate. These tests include blood tests to check your blood cell counts and liver function.

3 treatment phase

You will receive the study medications, loncastuximab tesirine and rituximab, through an intravenous infusion. This means the medication will be administered directly into your vein.

The dosage and frequency of the medications will be determined by the study protocol. You will be informed about the schedule and duration of each treatment cycle.

4 monitoring and follow-up

Throughout the study, regular monitoring will be conducted to assess your response to the treatment. This includes physical examinations, blood tests, and imaging studies.

You will be asked to report any side effects or changes in your health. The study team will provide guidance on managing any adverse effects.

5 end of treatment

At the end of the treatment phase, a final assessment will be conducted to evaluate the overall response to the study medications.

You will be informed about the results and any further steps, if necessary.

Who Can Join the Study?

  • Must be male or female.
  • Must have a confirmed diagnosis of Diffuse Large B-cell Lymphoma (DLBCL), High-Grade B-cell Lymphoma (HGBCL), or Grade 3b Follicular Lymphoma (FL).
  • Must have a measurable disease, which means the disease can be measured by medical tests.
  • Must be in Stages I-IV of the disease, which refers to the extent or severity of the disease.
  • Must have an ECOG Performance Status of 0-2. This is a scale used to assess how the disease affects daily living abilities. A score of 3 is allowed if the decline is due to lymphoma and can be improved by treatment.
  • Must have adequate organ function based on specific blood test results:
    • Absolute neutrophil count (a type of white blood cell) of at least 1.0 x 10^3/µL.
    • Platelet count of at least 75 x 10^3/µL without recent transfusion.
    • Liver enzymes (ALT, AST, GGT) should be no more than 2.5 times the normal limit.
    • Total bilirubin should be no more than 1.5 times the normal limit, except for certain conditions.
    • Creatinine clearance (a measure of kidney function) should be more than 30 mL/min.
  • Women of childbearing potential must use effective birth control during the study and for 12 months after the last treatment. Men must use a condom or practice abstinence during the study and for 7 months after the last treatment.
  • For Cohort A:
    • Must be considered unfit based on specific criteria, including being 80 years or older and meeting certain scores on daily living activities and health assessments.
  • For Cohort B:
    • Must be considered frail based on specific criteria, including being 80 years or older with certain scores on daily living activities and health assessments, or being 65-79 years old with specific heart conditions that make certain treatments unsuitable.

Who Cannot Join the Study?

  • Patients who have already received treatment for their lymphoma.
  • Patients who are not considered unfit or frail. Unfit means not in good health, and frail means weak or delicate.
  • Patients who do not have cardiac comorbidities. This means they do not have other heart-related health issues.
  • Patients who are eligible for standard treatment called R-mini-CHOP. This is a common treatment for certain types of lymphoma.
  • Patients who are not part of the specified age range for the study.
  • Patients who do not meet the gender requirements for the study.
  • Patients who are not considered part of a vulnerable population. This means they are not in a group that needs special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario De Navarra Pamplona Spain

Other Sites

Site Name City Country Status
Hospital Universitario Ramon Y Cajal Madrid Spain
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy
Hospital Universitario Fundacion Jimenez Diaz Madrid Spain
Hospital Arnau De Vilanova De Valencia Valencia Spain
Istituto Europeo Di Oncologia S.r.l. Milan Italy
Hospital Del Mar Barcelona Spain
Universita Degli Studi Di Brescia Brescia Italy
Hospital San Pedro De Alcantara Caceres Spain
Amqhoza Oydhnmrqsad Nvdzncqxu So Aqgvbqt E Bbegin E C Avjnaa Agevruiaorh Alexandria Italy
Ckctiii Ucgyrarfgpb De Nnqpxbd Madrid Spain
Hqpvyoyi Uvzferqaccmlu Mbfxdrg Dg Vehabfxxga Santander Spain
Ijensltx Cgtbog Diahunrdzmcvfgmdr L'hospitalet De Llobregat Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Not recruiting
25.03.2023
Spain Spain
Not recruiting
25.03.2023

Trial locations

Investigated drugs:

Loncastuximab Tesirine is a type of medication known as an antibody-drug conjugate. It is designed to target and attach to specific cancer cells, particularly those found in certain types of lymphoma. Once attached, it delivers a small dose of chemotherapy directly to the cancer cells, which helps to kill them while minimizing damage to healthy cells. This targeted approach aims to reduce side effects compared to traditional chemotherapy.

Rituximab is a medication that is used to treat certain types of cancer, including lymphoma. It works by targeting a specific protein found on the surface of cancer cells, which helps the body’s immune system to recognize and destroy these cells. Rituximab is often used in combination with other cancer treatments to improve their effectiveness.

Diffuse Large B-Cell Lymphoma – Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma that originates in the B-cells, which are a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. The disease often begins with a painless swelling in the neck, armpit, or groin due to enlarged lymph nodes. As it progresses, it can spread to other parts of the body, including the central nervous system. Symptoms may include fever, night sweats, and weight loss. The progression of DLBCL can vary, with some cases advancing quickly while others may develop more slowly.

Trial ID:
2022-501601-12-00
Protocol code:
ADCT-402-203
NCT ID:
NCT05144009
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark